Bristol Myers, Bluebird Gets FDA OK for Abecma in Multiple Myeloma >BMY BLUE
Bristol Myers, Bluebird Gets FDA OK for Abecma in Multiple Myeloma >BMY BLUE
DJ Bristol Myers, Bluebird Gets FDA OK for Abecma in Multiple Myeloma >BMY BLUE
By Colin Kellaher
Bristol Myers Squibb Co. and bluebird bio Inc. said the U.S. Food and Drug Administration approved Abecma for the treatment of adults with the blood cancer multiple myeloma.
The companies said the approval covers the CAR T cell immunotherapy formerly known as idecabtagene vicleucel, or ide-cel, for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy.
New York-based Bristol Myers and bluebird, a Cambridge, Mass., biotechnology company, are jointly developing and commercializing Abecma in the U.S. For bluebird, the FDA nod marks its first approved treatment in oncology and first approved treatment in the U.S.
Shares of bluebird, which closed Friday at $29.98, rose more than 9% in premarket trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 29, 2021 07:23 ET (11:23 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Bristol Myers, Bluebird Gets FDA OK for Abecma in Multiple Myeloma >BMY BLUE
DJ百時美施貴寶，藍鳥獲得FDA批准用於Abecma多發性骨髓瘤>BMY藍
By Colin Kellaher
科林·凱萊赫(Colin Kellaher)著
Bristol Myers Squibb Co. and bluebird bio Inc. said the U.S. Food and Drug Administration approved Abecma for the treatment of adults with the blood cancer multiple myeloma.
百時美施貴寶公司(Bristol Myers Squibb Co.)和藍鳥生物公司(Bluebird Bio Inc.)表示，美國食品和藥物管理局(FDA)批准阿貝瑪用於治療成人血癌多發性骨髓瘤。
The companies said the approval covers the CAR T cell immunotherapy formerly known as idecabtagene vicleucel, or ide-cel, for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy.
兩家公司表示，批准範圍包括CAR T細胞免疫療法，前身為idecabtagene vicleucel，或ide-cel，適用於經過四種或四種以上先前治療後復發或難治性多發性骨髓瘤的成年人。
New York-based Bristol Myers and bluebird, a Cambridge, Mass., biotechnology company, are jointly developing and commercializing Abecma in the U.S. For bluebird, the FDA nod marks its first approved treatment in oncology and first approved treatment in the U.S.
總部設在紐約的百時美施貴寶公司和位於馬薩諸塞州劍橋市的生物技術公司Bluebird正在美國聯合開發Abecma並將其商業化。FDA的認可標誌着該公司首次在腫瘤學領域獲得批准，也是第一次在美國獲得批准的治療方法。
Shares of bluebird, which closed Friday at $29.98, rose more than 9% in premarket trading Monday.
藍鳥的股價在週一盤前交易中上漲超過9%，上週五收於29.98美元。
Write to Colin Kellaher at colin.kellaher@wsj.com
寫信給Colin Kellaher，電子郵件：colin.kellaher@wsj.com
(END) Dow Jones Newswires
(完)道瓊通訊社
March 29, 2021 07:23 ET (11:23 GMT)
2021年3月29日東部時間07：23(格林尼治標準時間11：23)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧